Irras
Irras (formerly IRRAS AB, now a ClearPoint Neuro subsidiary) develops the IRRAflow intelligent catheter-based neurosurgical irrigation and drainage system. It serves neurosurgeons, neurosurgical centers, and biologics/gene-therapy delivery partners via ClearPoint Neuro's enterprise sales channels.
- Company typePublic
- Founded1996
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Irras does
Irras (formerly IRRAS AB) is a commercial-stage medical technology company focused on intelligent fluid management for neurosurgery. Its flagship product, the IRRAflow System, is an automated, dual-lumen catheter-based irrigation and drainage platform that combines an Intelligent Digital Pump, an Intelligent Cassette (ICDS 030), a Dual-Lumen Catheter (ICAT 030), a Cranial Access Bolt (ICB 010), and active fluid exchange control software (ICCU 020, v4.2.75.3 and v4.2.109.3) to deliver active intracranial fluid exchange, replacing passive external ventricular drainage. Post-acquisition in December 2025, IRRAS AB and IRRAS USA, Inc. operate as wholly-owned subsidiaries of ClearPoint Neuro (NASDAQ: CLPT), and the IRRAflow line is now distributed alongside ClearPoint's MRI-guided Navigation System, ClearPoint Prism Neuro Laser, SmartFrame OR, ClearPoint Array Platform, ClearPoint Maestro Brain Model, ClearPoint Pre-Clinical Orchestra, and SmartFlow Neuro Cannula.
The company generates revenue primarily through hardware and consumable sales of neurosurgical navigation systems and irrigation platforms. Distribution is via ClearPoint Neuro's enterprise field-sales organization targeting neurosurgeons and neurosurgical centers globally, supplemented by direct customer-service ordering, multi-language e-IFU documentation, and digital channels including YouTube training content, the ClearPoint of View newsletter, on-demand webinars, and industry conferences. The combined ClearPoint Neuro entity has guided FY2025 revenue of $52-56 million (with Q3 2025 at $8.9 million, missing $9.8 million consensus) and 16% Y/Y organic growth in Q1 2026. A revenue-sharing arrangement on specified IRRAS products is part of the acquisition consideration.
Beyond standalone neurosurgery, the company is positioned as an enabling technology for cell and gene therapy delivery to the brain. Its products are required administration tools for uniQure's AMT-130 Huntington's disease gene therapy, with uniQure planning an accelerated approval BLA submission in Q3 2026 based on 3-year Phase 1/2 analysis, and potential combined revenue upside exceeding $100 million annually at peak per source commentary. Customer concentration is anchored around hospital and neurosurgical center accounts served via ClearPoint's US headquarters (Solana Beach, CA), manufacturing facility (Carlsbad, CA), and European office (Guildford, UK), with headcount reported in the 11-50 band and ongoing regulatory and capital-structure interactions with Oberland Capital affiliates (CALW SA LLC, TPC Investments III LP) per a December 2025 consent agreement.
Irras firmographics
Firmographics- Name
- Irras
- Legal name
- ClearPoint Neuro, Inc.
- Website
- https://irras.com
- Company type
- Public
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Irras (formerly IRRAS AB, now a ClearPoint Neuro subsidiary) develops the IRRAflow intelligent catheter-based neurosurgical irrigation and drainage system. It serves neurosurgeons, neurosurgical centers, and biologics/gene-therapy delivery partners via ClearPoint Neuro's enterprise sales channels.
- Ownership category
- akta.pro rank
Where Irras is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Irras business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Revenue from sale of neurosurgical navigation systems, IRRAflow systems, and related consumables and components. ClearPoint reported Q3 2025 revenue of $8.9 million and full-year 2025 guidance of $52-56 million.
- IRRAS Product Revenue Share: Revenue-sharing arrangement on specific IRRAS product sales following ClearPoint's acquisition of IRRAS Holdings, involving $5.0 million cash payment and 1,325,000 shares of ClearPoint common stock.
- Partnership Revenue (AMT-130): Potential revenue from products required for uniQure's AMT-130 gene therapy administration. Article suggests over $100 million in annual revenue possible at peak if approved next year.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Direct ordering through customer service |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Irras product offering
Product offeringCore offering
Irras develops and manufactures the IRRAflow System, an intelligent external ventricular drainage and irrigation platform for neurosurgical procedures, including the IRRAflow Intelligent Digital Pump, Active Fluid Exchange System with software control, Dual-Lumen Catheter, Intelligent Cassette, and Cranial Access Kit. Following the December 2025 acquisition by ClearPoint Neuro, Irras products are distributed through ClearPoint's hospital and neurosurgical center sales channels alongside the ClearPoint Navigation System and SmartFlow Neuro Cannula.
Product overview
ClearPoint Neuro offers the IRRAflow System, a comprehensive neurosurgical irrigation and drainage platform acquired from IRRAS. The system comprises multiple integrated components including the Intelligent Digital Pump, Active Fluid Exchange System with software, Dual-Lumen Catheter, Cranial Access Bolt, and Drainage Collection System. Following the 2025 acquisition, IRRAS products are now distributed through ClearPoint Neuro's portfolio. The company also provides related neurosurgical navigation and delivery products including the ClearPoint Navigation System, SmartFlow Neuro Cannula, and ClearPoint Array Platform for brain and spine procedures.
Differentiator
Problem solved
Functional benefit
Brands
- IRRAflow: Intelligent catheter-based fluid exchange system for neurosurgical procedures
- ClearPoint Prism Neuro Laser System
- ClearPoint Navigation System
- ClearPoint Array Platform
- SmartFrame OR
- ClearPoint Maestro Brain Model
- ClearPoint Pre-Clinical Orchestra
- SmartFlow Neuro Cannula
Products and services
- IRRAflow System A comprehensive external ventricular drainage and irrigation system for neurosurgical procedures featuring intelligent fluid exchange capabilities for automated intracranial pressure management, designed for neurosurgeons and neurosurgical centers performing brain and spine procedures.
Quantifiable outcome
- External ventricular drain market reaching $6.74 billion by 2030
- +1 more outcomes
Companies that use Irras
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
Irras technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Irras partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- uniQurecoreClearPoint Neuro's products are required for uniQure's AMT-130 gene therapy administration. The FDA reversed its stance accepting 3-year analysis from Phase 1/2 studies as primary basis for accelerated approval BLA submission planned for Q3 2026. AMT-130 could generate over $100 million in annual revenue for ClearPoint at peak if approved next year.
Scale indicators8 records
Recent moves5 records
Expansion highlights6 records
Irras competitors and assessment
Company assessmentDirect peers
- Brainlab: Surgical navigation and planning software specialist for neurosurgery, spine, and radiotherapy. Directly competes with the ClearPoint Navigation System in MRI-guided neurosurgical procedures.
- Penumbra: Neurovascular-focused medtech company with similar revenue scale (~$1B) and overlapping call point in hospital neurosurgery and neuro-interventional suites. Comparable commercial-stage medical technology profile targeting neurological specialists.
- Integra LifeSciences: Specialty neurosurgery company with EVD catheters, intracranial pressure monitors, and neurosurgical instruments. Most direct peer to IRRAflow's fluid management and drainage franchise in neurocritical care.
Broad incumbents
- Elekta: Established player in radiation therapy and stereotactic neurosurgery, with the Leksell Gamma Knife and linear accelerators. Overlaps with the broader neurosurgical intervention market where ClearPoint/Irras sells.
- Medtronic: Largest medtech incumbent with a neurosurgery portfolio including Becker external ventricular drains and StealthStation surgical navigation. Direct overlap with both ClearPoint Navigation and IRRAflow product categories, with substantially greater scale and distribution.
- Stryker: Diversified medtech incumbent with a Neurosurgical division offering navigation, powered instruments, and disposables. Competes across multiple categories that overlap with ClearPoint/Irras's portfolio.
Regional players
- NovaBay Pharmaceuticals: Small-cap commercial-stage medical company at similar revenue and headcount scale to ClearPoint Neuro/Irras, providing a useful scale and capital-efficiency comparable for a publicly-traded micro-cap medical device business.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
Irras social profiles
Digital presenceIrras financial estimates
Financial estimateRevenue estimate
Valuation estimate
Irras leadership team
Management profileNumber of profiles
Profiles4 records
Irras subsidiaries and ownership
Company hierarchySubsidiaries2 records
Irras funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Irras M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Irras
What does Irras do?
Irras develops and manufactures the IRRAflow System, an intelligent external ventricular drainage and irrigation platform for neurosurgical procedures, including the IRRAflow Intelligent Digital Pump, Active Fluid Exchange System with software control, Dual-Lumen Catheter, Intelligent Cassette, and Cranial Access Kit. Following the December 2025 acquisition by ClearPoint Neuro, Irras products are distributed through ClearPoint's hospital and neurosurgical center sales channels alongside the ClearPoint Navigation System and SmartFlow Neuro Cannula.
Is Irras a public or private company?
Irras is a public company. It is classified as corporate owned and is currently operating.
When was Irras founded?
Irras was founded in 1996. It employs 11 to 50 people.
Where is Irras based?
Irras is headquartered in San Diego, United States, in the North America region.
How does Irras make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are IRRAS Product Revenue Share and partnership Revenue (AMT-130).
Who are Irras's main competitors?
Direct peers on record are Brainlab, Penumbra and Integra LifeSciences. Broad incumbents are Elekta, Medtronic and Stryker. NovaBay Pharmaceuticals is listed as a regional player.
Does Irras have an API?
No public API is recorded for Irras.